| 3.14 Data as of 4:00pm ET |  +0.01 / +0.32%Today’s Change | 2.94 Today|||52-Week Range 7.47 | -29.11% Year-to-Date |
| ENZN July Options Begin Trading May 20 / TheStreet.com |
| Previous close | 3.13 |
| Today’s open | 3.14 |
| Day’s range | 3.11 - 3.18 |
| Volume | 86,296 |
| Average volume (3 months) | 325,052 |
| Market cap | $136.8M |
| Dividend yield | -- |
| Earnings growth (last year) | +85.00% |
| Earnings growth (this year) | +666.67% |
| Earnings growth (next 5 years) | +53.00% |
| Revenue growth (last year) | -1.10% |
| P/E ratio | NM |
| Price/Sales | 4.86 |
| Price/Book | 1.76 |
| Today’s change | Today’s % change | |
|---|---|---|
| ALIMAlimera Sciences Inc | +0.04 | +0.91% |
| KBIOKaloBios Pharmaceuti... | +0.05 | +0.86% |
| PTXPernix Therapeutics ... | -0.04 | -1.13% |
| APPAA.P. Pharma Inc | -0.01 | -1.15% |
| Last reporting date | -- |
| EPS forecast (this quarter) | -- |
| Annual revenue (last year) | $42.6M |
| Annual profit (last year) | -$2.8M |
| Net profit margin | -6.53% |
Sector Health Technology |
Industry Biotechnology |
Director, Chief Executive & Operating Officer Geordie W. Hebard, III, MBA |
Senior Vice President-Research & Development Charles D. Conover, PhD, MBA |
Corporate headquarters Piscataway, New Jersey |
.
